378 related articles for article (PubMed ID: 32358063)
1. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
[TBL] [Abstract][Full Text] [Related]
2. Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells.
Zhang H; Wu H; Guan J; Wang L; Ren X; Shi X; Liang Z; Liu T
Oncotarget; 2015 Feb; 6(5):3085-97. PubMed ID: 25609203
[TBL] [Abstract][Full Text] [Related]
3. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Singh S; Srivastava SK; Bhardwaj A; Owen LB; Singh AP
Br J Cancer; 2010 Nov; 103(11):1671-9. PubMed ID: 21045835
[TBL] [Abstract][Full Text] [Related]
4. EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway.
Wang Z; Jiang J; Qin T; Xiao Y; Han L
J Cell Mol Med; 2019 Apr; 23(4):2678-2688. PubMed ID: 30761741
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Catenacci DV; Junttila MR; Karrison T; Bahary N; Horiba MN; Nattam SR; Marsh R; Wallace J; Kozloff M; Rajdev L; Cohen D; Wade J; Sleckman B; Lenz HJ; Stiff P; Kumar P; Xu P; Henderson L; Takebe N; Salgia R; Wang X; Stadler WM; de Sauvage FJ; Kindler HL
J Clin Oncol; 2015 Dec; 33(36):4284-92. PubMed ID: 26527777
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
Mayr C; Neureiter D; Pichler M; Berr F; Wagner A; Kiesslich T; Namberger K
Mol Med Rep; 2015 Aug; 12(2):2247-52. PubMed ID: 25846744
[TBL] [Abstract][Full Text] [Related]
7. Cellular context-dependent interaction between cancer and stellate cells in hetero-type multicellular spheroids of pancreatic tumor.
Nam S; Khawar IA; Park JK; Chang S; Kuh HJ
Biochem Biophys Res Commun; 2019 Jul; 515(1):183-189. PubMed ID: 31133378
[TBL] [Abstract][Full Text] [Related]
8. Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk.
Averett C; Bhardwaj A; Arora S; Srivastava SK; Khan MA; Ahmad A; Singh S; Carter JE; Khushman M; Singh AP
Carcinogenesis; 2016 Nov; 37(11):1052-1061. PubMed ID: 27609457
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
10. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Xu J; Liu S; Yang X; Cao S; Zhou Y
Life Sci; 2020 Dec; 263():118523. PubMed ID: 33039386
[TBL] [Abstract][Full Text] [Related]
11. HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.
Cao F; Li J; Sun H; Liu S; Cui Y; Li F
Oncol Rep; 2015 Apr; 33(4):1883-9. PubMed ID: 25672829
[TBL] [Abstract][Full Text] [Related]
12. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
Amrutkar M; Aasrum M; Verbeke CS; Gladhaug IP
BMC Cancer; 2019 Jun; 19(1):596. PubMed ID: 31208372
[TBL] [Abstract][Full Text] [Related]
13. Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance.
Wang L; Liu X; Zhou Q; Sui M; Lu Z; Zhou Z; Tang J; Miao Y; Zheng M; Wang W; Shen Y
Biomaterials; 2017 Nov; 144():105-118. PubMed ID: 28837958
[TBL] [Abstract][Full Text] [Related]
14. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
[TBL] [Abstract][Full Text] [Related]
15. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
16. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer.
Khan S; Setua S; Kumari S; Dan N; Massey A; Hafeez BB; Yallapu MM; Stiles ZE; Alabkaa A; Yue J; Ganju A; Behrman S; Jaggi M; Chauhan SC
Biomaterials; 2019 Jul; 208():83-97. PubMed ID: 30999154
[TBL] [Abstract][Full Text] [Related]
17. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
Arora S; Bhardwaj A; Singh S; Srivastava SK; McClellan S; Nirodi CS; Piazza GA; Grizzle WE; Owen LB; Singh AP
J Biol Chem; 2013 Jul; 288(29):21197-21207. PubMed ID: 23740244
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
19. Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.
Carapuça EF; Gemenetzidis E; Feig C; Bapiro TE; Williams MD; Wilson AS; Delvecchio FR; Arumugam P; Grose RP; Lemoine NR; Richards FM; Kocher HM
J Pathol; 2016 Jul; 239(3):286-96. PubMed ID: 27061193
[TBL] [Abstract][Full Text] [Related]
20. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
